In Vitro Evaluation of Extemporaneously Compounded Slow-Release Capsules Containing Morphine Sulfate or Oxycodone Hydrochloride
Author(s): Glowiak Dana L, Green Julie L, Bowman Bill J
Issue: Mar/Apr 2005 - Health and Wellness
View All Articles in Issue
Page(s): 157-164
Download in electronic PDF format for $75
Abstract: The in vitro performance of extemporaneously compounded morphine sulfate and oxycodone hydrochloride slow-release capsules was evaluated. Capsules containing varying amounts of morphine sulfate (15, 60, 200 mg) or oxycodone hydrochloride (10, 80, 200 mg) were prepared and provided by a local pharmacy. The capsules also contained 40% Methocel E4M Premium to slow the release of their active ingredient and sufficient lactose to fill the capsules. Three batches of each capsule strength were prepared, and replicates from each batch were evaluated using United States Pharmacopeia dissolution apparatus II. Samples were taken at regular time intervals over 24 hours. After 1 hour the pH of the dissolution medium was adjusted from 1.2 to 4.0, and after 2 hours the pH was adjusted to 6.8. The amount of drug released at each time point was determined spectrophotometrically. The compounded capsules released 14% to 23%, 67% to 85% and 93% to 98% of their active ingredient after 0.5, 4 and 12 hours, respectively. The relative standard deviations between the replicates from each batch were less than 10% for most time points. The percent of drug released over the first 4 hours was linear (r2=0.9409-0.9999) when plotted versus time1/2, indicating adherence to the simplified Higuchi model. Statistical analysis of the Higuchi dissolution constants indicated a significant difference (P<0.05) between batch No. 3 and the other two batches of 200-mg oxycodone hydrochloride capsule. There was also a statistical difference between most of the Higuchi dissolution constants for the different-strength slow-release capsules and between most slow-release capsules and equivalent strength controlled-release manufactured tablets (P< 0.05). Using 40% Methocel E4M Premium slowed the release of morphine sulfate and oxycodone hydrochloride from extemporaneously compounded capsules. The in vitro performance of the slow-release capsules showed little intrabatch variation, and only one preparation showed statistically significant interbatch variation, indicating reproducible and robust formulations. Even though changing the quantity of the formulation ingredients altered the release characteristics of the slow-release capsules, which also varied from that of equivalent-strength controlled-release tablets, their release profiles were similar. Further testing is needed to determine whether these differences are clinically significant.
Related Keywords:
morphine sulfate, oxycodone hydrochloride, slow-release capsules, pain management, pain control
Related Articles from IJPC |
Title/Author
(Click for Abstract / Details / Purchase) |
Issue/Page
View/Buy |
In Vitro Evaluation of Extemporaneously Compounded Slow-Release Capsules Containing Morphine Sulfate or Oxycodone Hydrochloride
Glowiak Dana L, Green Julie L, Bowman Bill J
|
Mar/Apr 2005
Pg. 157-164
|
Release of Morphine Sulfate from Compounded Slow-Release Capsules: The Effect of Formulation on Release
Bogner Robin H, Szwejkowski Jessica, Houston Alana
|
Sep/Oct 2001
Pg. 401-405
|
In Vitro Studies on the Release of Morphine Sulfate from Compounded Slow-Release Morphine-Sulfate Capsules
Webster Kathy D, Al-Achi Antoine, Greenwood Robert
|
Sep/Oct 1999
Pg. 409-411
|
Kinetic Analysis of Drug Release from Compounded Slow-release Capsules of Liothyronine Sodium (T3)
Bakhteyar Hamid, Cassone Clayton, Kohan Hamed Gilzad, Sani Shabnam N
|
Sep/Oct 2017
Pg. 418-425
|
Compounding Slow-release Capsules: A Comprehensive Review and an Excel Spreadsheet for Faster Calculation of Excipients
Zur Eyal
|
Jan/Feb 2013
Pg. 10-22
|
Oxycodone 25-mg Slow-Release Capsules
Allen Loyd V Jr
|
Jan/Feb 2002
Pg. 49
|
Compounding of Slow-release Niacinamide Capsules: Feasibility and Characterization
Radojkovic Branko, Milic Jela, Calija Bojan
|
Sep/Oct 2012
Pg. 434-437
|
Physical and Chemical Stability of Low and High Concentrations of Morphine Sulfate with Clonidine Hydrochloride Packaged in Plastic Syringes
Xu Quanyun A, Trissel Lawrence A, Pham Lien
|
Jan/Feb 2002
Pg. 66-69
|
Physical and Chemical Stability of Low and High Concentrations of Morphine Sulfate with Bupivacaine Hydrochloride Packaged in Plastic Syringes
Trissel Lawrence A, Xu Quanyun A, Pham Lien
|
Jan/Feb 2002
Pg. 70-73
|
Morphine Sulfate Slow-Release Suppositories
Allen Loyd V Jr
|
Jan/Feb 1997
Pg. 32-33
|
Physical Stability and Release Profile of Compounded Gabapentin Containing Pluronic Lecithin Organogel for Neuropathic Pain Management
Hong Eun Ji, Sumanasekera Wasana, Le Uyen Minh
|
Jan/Feb 2022
Pg. 65-71
|
Oxycodone Hydrochloride 10-mg and Dextromethorphan 20-mg capsules
Allen Loyd V Jr
|
May/Jun 2009
Pg. 246
|
Custom-Compounded Micronized Hormones in a Slow-Release Capsule Matrix
Timmons Evelyn D, Timmons Steven P
|
Sep/Oct 2002
Pg. 379
|
Oxycodone Hydrochloride 5-mg and Acetaminophen 325-mg per 5-mL Oral Solution
Allen Loyd V Jr
|
Mar/Apr 2015
Pg. 148
|
Progesterone 100-mg, Melatonin 1-mg, and L-Theanine 200-mg Slow-Release Capsules
Allen Loyd V Jr
|
Jan/Feb 2020
Pg. 62
|
Triple Estrogen 2.5-mg Slow-Release Capsules
Allen Loyd V Jr
|
Sep/Oct 1999
Pg. 401
|
Liothyronine Sodium (T3) 5-mcg/Hydrocortisone 5-mg Slow-Release Capsules
Allen Loyd V Jr
|
Nov/Dec 2008
Pg. 545
|
Liothyronine Sodium (T3) 5-mcg/Selenium 100-mcg Slow-Release Capsules
Allen Loyd V Jr
|
Nov/Dec 2008
Pg. 547
|
Liothyronine Sodium (T3) 5-mcg Slow-Release Capsules
Allen Loyd V Jr
|
Nov/Dec 2008
Pg. 548
|
Stability of Morphine Sulfate in Polypropylene Infusion Bags for Use in Patient-Controlled Analgesia Pumps for Postoperative Pain Management
Nguyen-Xuan Tho, Griffiths William, Kern Christian, Van Gessel Elisabeth, Bonnabry Pascal
|
Jan/Feb 2006
Pg. 69-73
|
Return to Top |